Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2019-11-27 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
独立董事关于第三届董事会第一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on the appointment of senior management at the company's third board meeting. It references compliance with relevant laws and regulations and confirms the qualifications and appointment of executives such as CEO, senior vice presidents, and financial officers. The document is short (1091 characters) and does not contain financial data or detailed financial performance. It is a formal announcement related to board/management changes rather than a full report or financial statement. Therefore, it fits the category of Board/Management Information (MANG).
2019-11-27 Chinese
2019年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance qualifications, and voting results of Betta Pharmaceuticals Co., Ltd.'s 2019 First Extraordinary General Meeting of Shareholders. It details the legal compliance of the meeting's call, conduct, and resolutions, including board and supervisory board elections and independent director remuneration. The document is not a financial report, earnings release, or management discussion but a legal opinion on the shareholder meeting's procedural validity and voting outcomes. This type of document corresponds to a Declaration of Voting Results & Voting Rights Announcements (DVA) filing, as it officially reports the voting results and validates the shareholder meeting procedures.
2019-11-22 Chinese
关于选举第三届监事会职工代表监事的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of a new employee representative supervisor to the company's third supervisory board. It includes details about the election process, the elected individual's background, and compliance with relevant laws and regulations. There is no financial data, no mention of financial results, no report attached or referenced, and no indication of a meeting presentation or voting results. The content focuses on management/board information, specifically about changes in the supervisory board composition. Therefore, the document fits best under 'Board/Management Information' (MANG). The document length is short and does not contain financial statements or detailed reports, confirming it is an announcement of a board change rather than a full report or other filing type.
2019-11-22 Chinese
2019年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2019 first extraordinary general meeting (临时股东大会) of Betta Pharmaceuticals Co., Ltd. It includes voting results on board of directors and supervisory board elections, remuneration for independent directors, and legal opinions on the meeting's validity. The content focuses on shareholder meeting decisions and voting outcomes rather than financial results or management discussion. It is not a full annual or interim report, nor an earnings release or audit report. The document is not a proxy solicitation or a report publication announcement. The key focus is on the official results of shareholder votes at a general meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters but contains substantive voting results, not just a brief announcement or link to a report, so it is not an RPA. Therefore, the best classification is DVA with high confidence.
2019-11-22 Chinese
关于召开2019年第一次临时股东大会的提示性公告
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the convening of a 2019 first extraordinary general meeting of shareholders (临时股东大会) for Betta Pharmaceuticals Co., Ltd. It includes information about the meeting date, voting methods (onsite and online), registration procedures, agenda items including board of directors and supervisory board elections, and instructions for proxy voting. The content focuses on the organization and procedural details of the shareholder meeting rather than the results of the vote or the meeting minutes. There is no indication that this document contains the actual voting results or a summary of the meeting outcomes. Therefore, it is not a Declaration of Voting Results (DVA). It is also not a Proxy Solicitation (PSI) because it does not solicit votes but rather informs about the meeting and voting procedures. The document is not a full Annual Report, Interim Report, or any financial report. It is a formal notice and detailed announcement about the shareholder meeting and voting process, which fits the category of AGM Information (AGM-R), as it provides materials and information related to the Annual or Extraordinary General Meeting.
2019-11-19 Chinese
关于对深圳证券交易所关注函的回复公告
Board/Management Information Classification · 95% confidence The document is a public announcement from the company regarding a reply to a concern letter from the Shenzhen Stock Exchange about the nomination of an independent director who holds multiple positions in other companies. It discusses compliance with regulatory rules on independent director nominations and governance implications. There is no financial data, no report attached or referenced as being published, and no mention of financial results or other report types. The content focuses on board/management information, specifically about the nomination and qualifications of a board member. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear focus on board nomination and governance compliance.
2019-11-11 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.